Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Other financing activities (2017)

Amicus Therapeutics (FOLD) has disclosed Other financing activities for 2 consecutive years, with $23.1 million as the latest value for Q4 2017.

  • For the quarter ending Q4 2017, Other financing activities changed N/A year-over-year to $23.1 million, compared with a TTM value of $23.1 million through Sep 2018, up 16619.57%, and an annual FY2017 reading of $23.1 million, up 31.98% over the prior year.
  • Other financing activities was $23.1 million for Q4 2017 at Amicus Therapeutics, up from $28000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $23.1 million in Q4 2017 and bottomed at $28000.0 in Q1 2017.